Abstract
Inflammatory bowel disease remains a difficult disease to effectively treat, especially fistulizing Crohn’s disease. Perianal fistulas in the setting of Crohn’s disease remain an area of unmet need with significant morbidity in this patient population. Up to one third of Crohn’s patients will have perianal fistulizing disease and current medical and surgical interventions are of limited efficacy. Thus, most patients experience significant morbidity, narcotic use, and loss of employment and end up with multiple surgical interventions. Mesenchymal stem cells (MSCs) have shown efficacy in phase 3 clinical trials, but considerable infrastructure challenges make MSCs limited with regard to scalability in clinical practice. Extracellular vesicles, being derived from MSCs and capturing the secretome functionality of MSCs, offer similar physiological utility regarding mechanism, while also providing an off the shelf regenerative medicine product that could be widely used in daily clinical practice.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Inflammatory bowel disease is not adequately treated with conventional therapy. |
Mesenchymal stem cell therapy has proven safe and effective in perianal fistulizing Crohn’s disease. |
Mesenchymal stem cell and/or Treg therapy may be effective for luminal disease. |
1 Introduction
Inflammatory bowel disease (IBD) is an idiopathic chronic transluminal inflammatory disorder of the gastrointestinal tract that is increasing in prevalence for unknown reasons [1, 2]. The Federal Drug Administration approved infliximab for the treatment of moderate to severe Crohn’s disease (CD) in 1998 [1]. This revolutionized the medical management of IBD from the use of glucocorticoids and immunosuppressants to monoclonal antibodies, or biologics, several more of which were subsequently licensed for use in IBD. Concurrently, greater use of a top-down or treat-to-target approach evolved, with the goal current medical therapy being not only symptom control but also mucosal healing as evaluated by endoscopy. Unfortunately, while biologics and, more recently, novel small molecule inhibitors, have improved disease control in many patients, at least one third of patients have primary nonresponse [2,3,4,5,6] and another third of patients experience secondary loss of response [7, 8]. Thus, despite several advanced therapies, and the increased morbidity and costs associated with cycling through these therapies, up to 60–80% with CD still require an intestinal resection [9, 10], and 20% with ulcerative colitis (UC) will undergo a proctocolectomy for medically refractory disease [11]. There is, therefore, an ongoing need for novel therapeutics. Cell-based therapies have recently been increasingly evaluated for the treatment of IBD and its associated phenotypes as one such novel class of potential therapeutics. The aim of this article is to walk through the current literature regarding cellular therapeutics for IBD, their limitations, and potential future technological advances to overcome these limitations.
2 Perianal Fistulizing Disease
Crohn’s disease (CD), a chronic transmural inflammatory disease of the gastrointestinal tract, continues to increase in incidence for unknown reasons [12]. According to population-based studies, at least 26% of patients with CD will develop perianal fistulas in the first two decades following diagnosis [13,14,15,16] particularly those with colonic and rectal involvement [13]. Up to 10% of women will develop a rectovaginal fistula [17, 18], another particularly devastating phenotype of perianal Crohn’s disease, which has a significant impact on quality of life due to the open communication from the rectum/anal canal to the vaginal wall [19]. Patients with rectovaginal fistula complain of stool and air per vagina, and some women will also report purulent discharge, dyspareunia, perineal pain and tenderness, and recurrent urinary tract infections [17, 20]. Perianal fistulizing patients experience significant morbidity due to pain, persistent drainage, recurrent perianal sepsis, and ongoing need to access medical care resulting in increased costs [21, 22] and impaired quality of life [22].
Unfortunately, perianal fistulizing Crohn’s disease is notoriously difficult to treat with 37% of patients experiencing refractory disease [23]. The most well studied agent for the treatment of fistulizing CD is infliximab, but less than one third of patients achieve fistula healing with this drug alone [19, 24]. In addition, biologic therapies have potential side effects including an increased risk of opportunistic infection [25]. Unfortunately, patients often cycle through several medications without benefit, all of which have potentially significant side effects. The lack of effectiveness means that > 90% undergo multiple surgical interventions [16] putting them at risk of incontinence [26]. The large number of surgical options including fistulotomy, plug and glue, anal/rectal flaps, or tissue interposition grafts, underscores that no one intervention is particularly effective. In addition, a normal rectum and anal canal are required for local surgical intervention, which is often not the situation in Crohn’s disease, greatly limiting the number of eligible patients for traditional surgical intervention.
Those with inflammation may have a seton placed (Fig. 1) in conjunction with initiation of infliximab, which can result in healing in up to 56% of patients; many, however, live with setons their entire life [27]. When surgical intervention is performed, long term success is limited by high rates of recurrence ranging between 25 and 50% [17, 28]. Therefore, up to 40% of patients will end up with a permanent diversion or a proctectomy, some with chronic non-healing perineal wounds [29, 30]. These results have spurred significant interest in identifying better treatment options that have the potential for improved efficacy without a risk of incontinence.
3 Utilizing a Novel Therapeutic
The goal of a novel therapeutic to treat inflammatory bowel disease if first safety and secondarily efficacy as measured by disease response and patient quality of life [31]. Consequently, designing clinical trials that capture safety, efficacy, and quality of life (QOL) are key to positioning a novel therapeutic in the future. For fistulizing disease, symptom improvement along with improved QOL may be considered a success for some, while others are looking for complete fistula closure. Given that fistula patients often have a luminal disease component, patients should be kept on concurrent medical therapy to optimize luminal disease control while surgically and locally addressing the fistula tract with a novel cell therapy. This is in contrast to the luminal disease studies in which patients undergo a washout of their medical therapy to understand the potential benefit of a novel cell therapy on their luminal disease control.
3.1 Mesenchymal Stem Cells for Fistulizing Crohn’s Disease
Mesenchymal stem cells (MSCs) exist in almost all tissues [32,33,34], and are believed to reduce inflammation due to their intrinsic immunomodulatory properties. Recently, success of MSCs in treating severe inflammatory disorders, such as graft-versus-host disease (GvHD) [35], systemic lupus erythematosus [36], myocardial infarction [37], multiple sclerosis [38], and Crohn’s disease (CD) [39] has highlighted the therapeutic benefit of MSCs [40, 41]. In addition to being multipotent, MSCs act as immunomodulators to regulate T-cell activity and promote tissue repair [42]. Their immunomodulatory properties are thought to be carried out by migration to sites of active inflammation or tissue injury, secretion of anti-inflammatory molecules, such as interleukin-10 (IL-10), HGF, TGFβ1 [43], and indoleamine 2,3-dioxygenase (IDO) [44], and paracrine signaling to nearby cells to maintain the local anti-inflammatory environment [45, 46]. By influencing cytokine secretion profiles, MSCs can modulate the function of various immune cell types including lymphocytes, dendritic cells, and macrophages. Therefore, MSCs’ ability to change the local inflammatory cell milieu, migrate to sites of inflammation, and dampen immune responses underscores the escalating interest in using MSCs to treat IBD.
Locally administered MSCs are a promising option for complex perianal fistulizing CD (Fig. 2); even the American Society of Colon and Rectal Surgeons have updated their national guidelines to reflect the current literature to support MSC utilization [47]. MSCs can be harvested from bone marrow or from adipose tissue. Depending on the medical need, they can be collected from the patient’s own body (autologous) or from another donor (allogenic). The first successful use of locally administered MSCs for the treatment of a refractory rectovaginal fistula in the setting of CD was reported in 2003 [48]. These promising results generated a wave of phase 1, phase 2, and phase 3 trials to study the safety and efficacy of using MSCs to treat perianal CD (Table 1). Despite the heterogeneity in protocols using allogeneic or autologous MSCs, derived from both bone marrow or adipose tissue, administered at various doses, delivered as a singular or repeat injection, and delivered with or without scaffolding, the results of all completed trials have been very encouraging with regard to both safety and efficacy [42, 49]. Safety has focused on the rate of perianal abscess formation and perianal pain to determine whether injection of MSCs increases either. Efficacy has been largely defined as epithelization of the external opening, lack of drainage to palpation of the fistula tract at the external opening and lack of a fluid collection greater than 2 cm × 2 cm × 3 cm in any two of three dimensions. Given there are no approved cell-derived therapeutics to date with the Food and Drug Administration (FDA) for perianal fistula, these endpoints have not yet been provided in FDA guidance documents, but have been consistently used across the clinical trials performed to date, and will likely be used for drug approval by regulatory authorities in the future.
With regard to safety, there have been no adverse or serious adverse events related to investigational product. Rather, the most common adverse events are pain at the injection site and perianal abscess formation which have been equivalent in the treatment and control groups. With regard to efficacy, data from a randomized placebo-controlled phase 3 clinical trial, ADMIRE, demonstrated significant efficacy as compared with placebo in the MSC treated group at six months (51 versus 36%; p = 0.021) and one year (56 versus 39%; p = 0.010) [50, 51].
Interestingly the durability of MSC healing has also been demonstrated by the long-term follow-up of ADMIRE clinical trial patients. Healing in the treatment versus placebo group was significantly improved at 6 months and this was maintained at 1 year, respectively [50, 51]. Even longer duration of follow-up found that the proportion of patients in ADMIRE with healed fistulas at 52, 104, and 156 weeks was 67, 54, and 54%, respectively, again underscored the durability of response over a longer follow up period [52]. Additionally, although a much smaller cohort, a group from Belgium showed that healing from a single dose of MSCs in Crohn’s perianal fistula was sustained to four years [53]
Given the promising healing rates in perianal disease in phase 3 clinical trials, additional phase 1B/2A clinical trials of approximately 20 patients have been performed showing safety and efficacy in complex perianal, rectovaginal, and pouch fistula phenotypes [54, 55]. This greatly expands the field’s experience with MSCs in multiple phenotypes of complex fistulizing disease, providing further data to support cell therapy in any phenotype of a Crohn’s related fistula. In addition, safety data has been reported in pediatric patients with Crohn’s-related perianal fistulizing disease [56].
3.2 Mesenchymal Stem Cells for Luminal Inflammatory Bowel Disease
Several animal studies have been conducted to demonstrate reversal of colitis with mesenchymal stem cells utilizing several modes of delivery including intraperitoneal injection [57, 58], direct rectal wall injection [59], intravenous delivery [59,60,61,62], and intra-arterial delivery. One study showed superiority of intravenous versus intraperitoneal delivery. However, again, due to the intravenous route resulting in pulmonary trapping, which can cause adverse effects such as embolus formation and post-transplantation pneumonitis, studies have focused on the safety and efficacy of intra-arterial delivery [63]. Thus, additional animal studies have now been performed demonstrating the safety of intra-arterial injection of MSCs specifically for the treatment of dextran sodium sulfate (DSS)-induced colitis. A group from Sweden injected 5 × 106 111In-oxine-labeled human decidual stromal cells (DSCs) into four rabbits via the superior mesenteric artery (SMA) using an angiographical system. The group found that selective injection of human DSCs to the rabbit SMA did not result in acute embolic complications or pulmonary trapping. Rather, selective injections to the SMA resulted in uptake distributed in the intestine supplied by the SMA and in the liver, indicating that this approach could significantly increase the fraction of injected DSCs reaching the target tissue without adverse events. Intravenous delivery corroborated pulmonary trapping. Another study looked at a study of mesenteric injection of adipose derived mesenchymal stem cells relieved colitis in rats without any safety concerns [64]. Another study looked at intra-arterial versus intra-venous delivery of MSCs intravenously versus intra-arterially and found that intra-arterial delivery was safe and had less uptake in the lungs [65].
Despite the large number of animal studies performed, only a handful of human studies have assessed systemic delivery of MSCs for IBD [66,67,68]. A study in patients with CD used Remestemcel-L, an allogeneic bone marrow derived MSC product (NCT00294112), which randomized patients to receive two infusions 1 week apart of either 2 million cells or 8 million cells/kg, intravenously. There were no reported infusion reactions, five mild adverse events unrelated to investigational product, and one serious adverse event (anemia) that were felt to be unrelated to investigational product. This phase II trial spurred a phase III clinical trial (Osiris protocol 610 NCT01233960) of four infusions over 2 weeks of either 600 million cells, 1200 million cells or placebo for medically refractory CD. The trial was stopped due to problems with protocol design and desire for open-label therapy, but there were no safety concerns. The only study of systemic MSCs for UC was a phase I/II trial of 70 UC patients treated by delivery into a peripheral vein or into the superior mesenteric artery versus placebo. Clinical response and remission were increased in the treatment group as compared to the control group, and there were no adverse reactions after MSC delivery [68]
Thus, overall, the intravenous deliver y of MSCs for medically refractory IBD has not significantly progressed. However, anecdotally, when we were treating patients in our own clinical trials of MSCs for the treatment of perianal Crohn’s fistulizing disease (ClinicalTrials.gov identifier: NCT04519671), we noted that proctitis would also improve after the direct injection near the internal opening of the fistula tract on the anal/rectal side. While previous clinical trials of the systemic delivery of MSCs for both luminal CD and UC have proven largely ineffective compared to conventional treatment approaches [66,67,68], none have used a method of direct targeted local delivery of cells, as has been utilized in clinical trials for perianal CD. Thus, because it has been well established that there is significant pulmonary trapping following intravenous delivery of MSCs [69], and there has been resolution of proctitis with direct injection, we sought to investigate the efficacy of MSCs delivered locally via endoscopic delivery, as is done in the setting of perianal disease, to treat the local site of inflammation directly. We performed two phase 1B/2A clinical trials of endoscopic delivery of MSCs in medically refractory ulcerative colitis and Crohn’s disease, both of which underscored the safety profile of MSC delivery and early limited efficacy [70, 71]. Future trials should be done to understand optimal dosing and dosing frequency with targeted efficacy outcomes.
3.3 Limitations of Mesenchymal Stem Cell Therapy
MSC properties vary depending on their tissue source within a patient, patient themselves, and culture conditions with process variation, all of which introduces variability and uncertainty into the cell-based treatment regimen. Donor age and sex affect the function of MSCs, and cell properties and functions differ between MSCs isolated from adipose tissue, umbilical cord, bone marrow, or other sites. While adipose MSCs are easier to harvest through liposuction or en bloc biopsy, no clinical trial has directly compared adipose versus bone marrow MSCs with regard to safety and efficacy for perianal CD. Nor has a clinical trial compared safety and efficacy of autologous versus allogeneic MSCs. Important strengths and weaknesses have been well established for each. Autologous cells are self-derived and will not evoke antibody responses with further treatments. However, patients are subjected to additional procedures for cell harvest that are not without risk and potential morbidity. Additional time and expense are then incurred for harvesting, expanding and testing the MSCs for sterility and viability prior to patient delivery and there is emerging evidence regarding the variability in MSC function across donors. Specific to CD is that MSCs from patients with CD do not appear as anti-inflammatory or immunomodulatory based on in vitro studies as compared to healthy control patients [72]. In contrast to autologous MSCs, allogeneic cells provide an off-the-shelf product that can be administered in a point-of-care fashion rather than requiring additional steps to harvest and expand the cells. In addition, since allogeneic MSCs are immunoprivileged with low expression levels of HLA class I and lack class II or costimulatory molecules, allogeneic MSCs may not generate antibodies in patients that would hinder efficacy with subsequent use. Nearly three times as many patients have been treated with allogeneic as compared to autologous MSCs. Similarly, nearly ten times as many patients have been treated with adipose derived MSC as compared with bone marrow MSC, likely due to the ease of adipose tissue harvest as compared with bone marrow harvest suggesting that ease of use is an important factor in MSC technology uptake.
Darvadstrocel (AlofiselTM), an allogenic adipose-derived viable MSC therapy, was approved in the European Union in 2018 and Japan in 2021 for the treatment of refractory complex perianal fistulizing CD in adults. Currently, it is the only MSC product approved for use by a regulatory body for the treatment of any phenotype of IBD. The US Food and Drug Administration (FDA) granted regenerative medicine advanced therapy (RMAT) designation to darvadstrocel in May of 2019 for complex perianal fistulas in adults with CD and its approval is currently under review as enrolment in the ADMIRE II phase III clinical trial was recently completed. The challenge with darvadstrocel is justifying the high cost of therapy when the placebo rate in the phase 3 clinical trial and subsequent follow up were so high; the delta in placebo and treatment was only 15%. This high placebo rate calls into question the actual utility of the MSCs, especially when the cost can be prohibitively high at £54,000 [50, 51].
In addition, while MSCs are promising regarding safety profile and clinical efficacy, the infrastructure required results in limited penetration to practice following approval. The challenge with viable MSCs is the infrastructure needed to deliver cell therapy and the limited number of sites with that capability. MSCs have a short shelf life of cell viability—approximately 48 h from the laboratory to the operating room—and are typically best used fresh, adding limiting complexity to procedures [31]. In addition, scalability and reproducibility is a challenge. The potential for tumorigenesis and teratoma formation is genuine. Lastly, there is a significant concern for alloimmunity. Timing of cell shipment, cost of shipment and product, limited starting material, and need for cell therapy pharmacies translates to limited clinical use occurring only in centers that have the required infrastructure and patients or healthcare systems that can afford the product. Thus, a secretome product offers the potential benefit of cell therapy while concurrently offering a scalable product, which could be offered in any clinical setting, regardless of clinical infrastructure.
3.4 Next Generation of Cell Therapy
There are well designed studies showing that paracrine effects mediated by the MSC secretome, including the extracellular vesicle (EV) compartments and noncompartmentalized biomolecules, are the most important aspect of MSC function related to local healing rather than transdifferentiation across cell types. In fact, one study using autologous bone marrow MSC found a significant increase in the percentage of circulating CD4+CD25 brightFoxP3+ regulatory T cells at 12 months (p < 0.01) and mucosal FoxP3+ regulatory T cells in the inflamed areas (at 12 months) (p < 0.001), suggesting that bone marrow MSCs are able to recruit relevant immune cells to local environment of the fistula. Therefore, the successes achieved with the use of viable MSC preparations to treat fistulas associated with perianal CD, as summarized above, suggest that a preparation of MSC-derived EVs may also be effective, safe, and considerably more convenient.
Preclinical studies have confirmed that EV therapy may be effective in the treatment of IBD. In the DSS-induced mouse model of colitis, human umbilical cord derived exosomes injected intravenously homed directly to the diseased colons within 12 h, and macrophage infiltration and disease severity were significantly reduced [73]. Anti-inflammatory IL-10 expression was reduced while expression of proinflammatory TNF-α, IL-1β, IL-6, iNOS, and IL-7 was decreased in the colons of these DSS-induced diseased mice. In another relevant study, human dental pulp MSCs were expanded, induced to overexpress HIF-1α, and primed with proinflammatory stimuli before harvesting the “boosted EVs” from the cultures [74]. The EVs were then shown to immunomodulate macrophages from an M1 proinflammatory phenotype to an immunosuppressive M2 phenotype in vitro, as well as following intraperitoneal injection, to increase the infiltrating M2:M1 ratio and attenuate disease status in a mouse TNB induced model of colitis. EVs derived from human placenta MSCs were evaluated in a recent phase I study wherein 5 of 11 patients with fistulizing disease showed complete tract resolution over 6 months; only one failed to show any improvement and no safety events were reported [75]. These studies are direct in vivo demonstrations of the potential for MSC EVs to favorably modify the inflammatory basis of colitis and contribute to disease resolution and support our hypothesis that direct injection of the IMP at the diseased area will promote resolution of inflammation-driven perianal fistulas associated with Crohn’s disease.
Given these preclinical studies, and potential with a MSC–EV-derived therapy, there are now clinical trials underway to study ExoFloTM, a MSC-derived EV product for the study of luminal medically refractory Crohn’s disease (IND27959; NCT05130983) via intravenous delivery, luminal medically refractory ulcerative colitis (IND27959; NCT05176366) via intravenous delivery, and refractory perianal Crohn’s disease (IND29323; NCT05836883) via direct injection. The results of these early clinical trial efforts will provide additional insight as to the next generation of cell therapy with EV therapy, providing an off the shelf, truly scalable regenerative medicine approach.
4 Beyond Mesenchymal Stem Cell Therapy—Regulatory T Cells
Regulatory T cells (Tregs) are nonredundant regulators of intestinal tolerance [76]. Quantitative and qualitative defects in mucosal Tregs have been identified in patients with Crohn’s disease leading to the hypothesis that correction of these defects may be a therapeutically tractable way to reset a disordered homeostatic immune response in the gut [77]. Over the past few years, modulation/enhancement of endogenous Tregs with low-dose IL-2 or an engineered derivative have been largely clinically ineffective. Therefore, attention has increasingly started to turn to the adoptive transfer of autologous Tregs, expanded in vitro and modified to traffic to the intestine. The most clinically advanced of these programs in refractory Crohn’s disease is the TRIBUTE study (NCT03185000), which involves the transfer of polyclonal Tregs that have been induced to express high levels of the gut homing integrin α4b7. The efficacy of this approach, either alone or in combination with MSCs/EVs in refractory or fistulizing disease remains to be determined.
5 Conclusions
Cell therapy offers a new frontier of medical therapy to treat inflammatory bowel disease. Much of the evidence to date comes from the use of cell therapy in perianal fistulizing Crohn’s disease. Fortunately, the studies to date have underscored the safety of cell therapy, and initial work has highlighted the potential efficacy. However, there are still several unanswered questions such as the mechanism of action of cell therapy on IBD and how to scale cell therapy to treat thousands of patients with IBD. This will need to be better illustrated in future studies.
References
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33.
Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38.
Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–50.
Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126(2):402–13.
Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–38.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94.
Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289–97.
Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553–63.
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54 e42 (quiz e30).
Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut. 1980;21(6):525–7.
Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME. Long-term quality of life in patients with Crohn’s disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum. 2007;50(12):2067–74.
Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice C. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125(5):1508–30.
Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875–80.
Hannaway CD, Hull TL. Current considerations in the management of rectovaginal fistula from Crohn’s disease. Colorectal Dis. 2008;10(8):747–55 (discussion 55–6).
Radcliffe AG, Ritchie JK, Hawley PR, Lennard-Jones JE, Northover JM. Anovaginal and rectovaginal fistulas in Crohn’s disease. Dis Colon Rectum. 1988;31(2):94–9.
Sands BE, Blank MA, Patel K, van Deventer SJ, Study AI. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2(10):912–20.
Andreani SM, Dang HH, Grondona P, Khan AZ, Edwards DP. Rectovaginal fistula in Crohn’s disease. Dis Colon Rectum. 2007;50(12):2215–22.
Chaparro M, Zanotti C, Burgueno P, Vera I, Bermejo F, Marin-Jimenez I, et al. Health care costs of complex perianal fistula in Crohn’s disease. Dig Dis Sci. 2013;58(12):3400–6.
Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Lopez-Sanroman A. Management of complex perianal Crohn’s disease. Ann Gastroenterol. 2017;30(1):33–44.
Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ. Disappointing durable remission rates in complex Crohn’s disease fistula. Inflamm Bowel Dis. 2014;20(11):2022–8.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85.
Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385-97 e10.
Soltani A, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis Colon Rectum. 2010;53(4):486–95.
Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9(2):98–103.
El-Gazzaz G, Hull T, Mignanelli E, Hammel J, Gurland B, Zutshi M. Analysis of function and predictors of failure in women undergoing repair of Crohn’s related rectovaginal fistula. J Gastrointest Surg. 2010;14(5):824–9.
Steele SR, Kumar R, Feingold DL, Rafferty JL, Buie WD, Standards Practice Task Force of the American Society of C, and Rectal S. Practice parameters for the management of perianal abscess and fistula-in-ano. Dis Colon Rectum. 2011;54(12):1465–74.
Wolff BG, Culp CE, Beart RW Jr, Ilstrup DM, Ready RL. Anorectal Crohn’s disease. A long-term perspective. Dis Colon Rectum. 1985;28(10):709–11.
Lightner AL, Ashburn JH, Brar MS, Carvello M, Chandrasinghe P, van Overstraeten AB, et al. Fistulizing Crohn’s disease. Curr Probl Surg. 2020;57(11): 100808.
Toma JG, Akhavan M, Fernandes KJ, Barnabe-Heider F, Sadikot A, Kaplan DR, Miller FD. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol. 2001;3(9):778–84.
Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 2004;22(7):1330–7.
Yoshimura K, Shigeura T, Matsumoto D, Sato T, Takaki Y, Aiba-Kojima E, et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol. 2006;208(1):64–76.
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–86.
Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467–75.
Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54–63.
Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. 2010;227(1–2):185–9.
García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416–23.
Gharibi T, Ahmadi M, Seyfizadeh N, Jadidi-Niaragh F, Yousefi M. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis. Cell Immunol. 2015;293(2):113–21.
Kimbrel EA, Kouris NA, Yavanian GJ, Chu J, Qin Y, Chan A, et al. Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev. 2014;23(14):1611–24.
Sebbagh AC, Rosenbaum B, Péré G, Alric H, Berger A, Wilhelm C, et al. Regenerative medicine for digestive fistulae therapy: benefits, challenges and promises of stem/stromal cells and emergent perspectives via their extracellular vesicles. Adv Drug Deliv Rev. 2021;179: 113841.
Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp immunol. 2007;149(2):353–63.
Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103(12):4619–21.
Horton JA, Hudak KE, Chung EJ, White AO, Scroggins BT, Burkeen JF, Citrin DE. Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. Stem Cells. 2013;31(10):2231–41.
Pezato R, de Almeida DC, Bezerra TF, Silva Fde S, Perez-Novo C, Gregorio LC, et al. Immunoregulatory effects of bone marrow-derived mesenchymal stem cells in the nasal polyp microenvironment. Mediators Inflamm. 2014;2014: 583409.
Lightner AL. Management of fistulas in patients with Crohn’s disease. Gastroenterol Hepatol (NY). 2021;17(11):533–5.
García-Olmo D, García-Arranz M, García LG, Cuellar ES, Blanco IF, Prianes LA, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18(5):451–4.
Wang H, Jiang HY, Zhang YX, Jin HY, Fei BY, Jiang JL. Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials. Stem Cell Res Ther. 2023;14(1):103.
Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281–90.
Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2018;154(5):1334-42 e4.
Panes J, Bouma G, Ferrante M, Kucharzik T, Nachury M, de la Portilla de Juan F, et al. INSPECT: a retrospective study to evaluate long-term effectiveness and safety of darvadstrocel in patients with perianal fistulizing Crohn’s disease treated in the ADMIRE-CD trial. Inflamm Bowel Dis. 2022.
Barnhoorn MC, Wasser M, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, et al. Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn’s disease perianal fistulas. J Crohns Colitis. 2020;14(1):64–70.
Lightner AL, Reese J, Ream J, Nachand D, Jia X, Dadgar N, et al. A phase IB/IIA study of ex vivo expanded allogeneic bone marrow derived mesenchymal stem cells for the treatment of perianal fistulizing Crohn’s disease. Dis Colon Rectum. 2023.
Lightner AL, Reese JS, Ream J, Nachand D, Dadgar N, Adams A, VanDenBossche A, Pineiro AO, Hull T. A phase IB/IIA study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of rectovaginal fistulizing Crohn's disease. Surgery. 2024;175(2):242–9.
Lightner AL, Otero-Pineiro A, Reese J, Ream J, Nachand D, Adams AC, VanDenBossche A, Kurowski JA. A phase I study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of pediatric perianal fistulizing Crohn's disease. Inflamm Bowel Dis. 2023;29(12):1912–9.
Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009;136(3):978–89.
Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58(7):929–39.
de la Portilla F, Yuste Y, Pereira S, Olano C, Maestre MV, Padillo FJ. Local mesenchymal stem cell therapy in experimentally induced colitis in the rat. Int J Stem Cells. 2018;11(1):39–47.
Goncalves Fda C, Schneider N, Pinto FO, Meyer FS, Visioli F, Pfaffenseller B, et al. Intravenous vs intraperitoneal mesenchymal stem cells administration: what is the best route for treating experimental colitis? World J Gastroenterol. 2014;20(48):18228–39.
He XW, He XS, Lian L, Wu XJ, Lan P. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig Dis Sci. 2012;57(12):3136–44.
Liang L, Dong C, Chen X, Fang Z, Xu J, Liu M, et al. Human umbilical cord mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid (TNBS)-induced colitis. Cell Transplant. 2011;20(9):1395–408.
Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683–92.
Fu ZQ, Zhou Q, Zhu S, Liu W. Anti-tumor mechanism of IL-21 used alone and in combination with 5-fluorouracil in vitro on human gastric cancer cells. J Biol Regul Homeost Agents. 2018;32(3):619–25.
Makela T, Takalo R, Arvola O, Haapanen H, Yannopoulos F, Blanco R, et al. Safety and biodistribution study of bone marrow-derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model. Cytotherapy. 2015;17(4):392–402.
Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut. 2010;59(12):1662–9.
Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12(1):64–71.
Hu J, Zhao G, Zhang L, Qiao C, Di A, Gao H, Xu H. Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Exp Ther Med. 2016;12(5):2983–9.
Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther. 2016;7:7.
Lightner AL, Dadgar N, Matyas C, Elliott K, Fulmer C, Khaitan N, et al. A phase IB/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis. Colorectal Dis. 2022;24(11):1358–70.
Lightner AL, Ream J, Nachand D, Fulmer C, Regueiro M, Steele SR. Remestemcel-L allogeneic bone marrow-derived mesenchymal stem cell product to treat medically refractory Crohn’s colitis: preliminary phase IB/IIA study. Br J Surg. 2022;109(8):653–5.
Anbazhagan M, Geem D, Venkateswaran S, Pelia R, Kolachala VL, Dodd A, et al. Characterization of intestinal mesenchymal stromal cells from patients with inflammatory bowel disease for autologous cell therapy. Stem Cells Transl Med. 2023;12(2):112–22.
Mao F, Wu Y, Tang X, Kang J, Zhang B, Yan Y, et al. Exosomes derived from human umbilical cord mesenchymal stem cells relieve inflammatory bowel disease in mice. Biomed Res Int. 2017;2017:5356760.
Gómez-Ferrer M, Amaro-Prellezo E, Dorronsoro A, Sánchez-Sánchez R, Vicente Á, Cosín-Roger J, et al. HIF-overexpression and pro-inflammatory priming in human mesenchymal stromal cells improves the healing properties of extracellular vesicles in experimental Crohn’s disease. Int J Mol Sci. 2021;22(20).
Pak H, Hadizadeh A, Heirani-Tabasi A, Soleimani M, Asbagh RA, Fazeli MS, et al. Safety and efficacy of injection of human placenta mesenchymal stem cells derived exosomes for treatment of complex perianal fistula in non-Crohn’s cases: clinical trial phase I. J Gastroenterol Hepatol. 2023;38(4):539–47.
Jacobse J, Li J, Rings E, Samsom JN, Goettel JA. Intestinal regulatory T cells as specialized tissue-restricted immune cells in intestinal immune homeostasis and disease. Front Immunol. 2021;12: 716499.
Clough JN, Omer OS, Tasker S, Lord GM, Irving PM. Regulatory T-cell therapy in Crohn’s disease: challenges and advances. Gut. 2020;69(5):942–52.
Garcia-Olmo D, Garcia-Arranz M, Garcia LG, Cuellar ES, Blanco IF, Prianes LA, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18(5):451–4.
Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416–23.
Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52(1):79–86.
Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn’s fistula: a phase I clinical study. Cell Transplant. 2013;22(2):279–85.
Lee WY, Park KJ, Cho YB, Yoon SN, Song KH, Kim DS, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells. 2013;31(11):2575–81.
Cho YB, Park KJ, Yoon SN, Song KH, Kim DS, Jung SH, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015;4(5):532–7.
Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60(6):788–98.
de la Portilla F, Alba F, Garcia-Olmo D, Herrerias JM, Gonzalez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28(3):313–23.
Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2015;149(4):918-27 e6.
Dietz AB, Dozois EJ, Fletcher JG, Butler GW, Radel D, Lightner AL, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2017;153(1):59-62 e2.
Barnhoorn MC, Wasser M, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, et al. Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn’s disease perianal fistulas. J Crohns Colitis. 2019.
Lightner AL, Reese J, Ream J, Nachand D, Jia X, Dadgar N, et al. A phase IB/IIA study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of perianal fistulizing Crohn’s disease. Dis Colon Rectum. 2023;66(10):1359–72.
Lightner AL, Reese J, Ream J, Nachand D, Jia X, Pineiro AO, et al. A phase IB/IIA study of allogeneic, bone marrow-derived, mesenchymal stem cells for the treatment of refractory ileal-anal anastomosis and peripouch fistulas in the setting of Crohn’s disease of the pouch. J Crohns Colitis. 2023;17(4):480–8.
Funding
Open access funding provided by SCELC, Statewide California Electronic Library Consortium.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Not applicable.
Conflict of interest
ALL: Consulting: Boomerang Medical; AB: Founder and Chief Scientific Officer of Vitabolus.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and materials
Not applicable.
Code availability
Not applicable.
Author contributions
All authors contributed to writing and editing of the manuscript.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Lightner, A.L., Irving, P.M., Lord, G.M. et al. Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives. BioDrugs 38, 527–539 (2024). https://doi.org/10.1007/s40259-024-00661-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-024-00661-6